UY37869A - Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvir - Google Patents
Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirInfo
- Publication number
- UY37869A UY37869A UY0001037869A UY37869A UY37869A UY 37869 A UY37869 A UY 37869A UY 0001037869 A UY0001037869 A UY 0001037869A UY 37869 A UY37869 A UY 37869A UY 37869 A UY37869 A UY 37869A
- Authority
- UY
- Uruguay
- Prior art keywords
- combination therapies
- parapoxvir
- vhb
- hepatitis
- viruses
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 241000283898 Ovis Species 0.000 abstract 1
- 241000700639 Parapoxvirus Species 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229960000980 entecavir Drugs 0.000 abstract 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a nuevas terapias de combinación de individuos infectados con VHB usando un Parapoxvirus ovis (PPVO) y al menos un fármaco antivírico adicional, por ejemplo, inhibidores de nucleósido, tales como Entecavir. Los métodos y los productos de combinación de acuerdo con la presente invención son seguros y adecuados para la inducción de una cura funcional en pacientes crónicamente infectados con VHB.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17189890 | 2017-09-07 | ||
EP17196684 | 2017-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37869A true UY37869A (es) | 2019-04-30 |
Family
ID=63442656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037869A UY37869A (es) | 2017-09-07 | 2018-09-07 | Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvir |
Country Status (20)
Country | Link |
---|---|
US (1) | US20200261520A1 (es) |
EP (1) | EP3678697A1 (es) |
JP (2) | JP2020533314A (es) |
KR (1) | KR20200051685A (es) |
CN (1) | CN111093697A (es) |
AU (1) | AU2018327688B2 (es) |
BR (1) | BR112020004539A2 (es) |
CA (1) | CA3075206A1 (es) |
CL (1) | CL2020000556A1 (es) |
CU (1) | CU20200016A7 (es) |
EC (1) | ECSP20016672A (es) |
GE (1) | GEP20237518B (es) |
IL (1) | IL273093A (es) |
MA (1) | MA50071A (es) |
MX (1) | MX2020002605A (es) |
PH (1) | PH12020500445A1 (es) |
SG (1) | SG11202001931WA (es) |
TW (1) | TW201919675A (es) |
UY (1) | UY37869A (es) |
WO (1) | WO2019048640A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3906970T3 (pl) | 2020-05-08 | 2022-10-24 | Aicuris Gmbh & Co. Kg | Parapokswirus do kondycjonowania i leczenia zakażeń koronawirusowych |
EP3906929A1 (en) | 2020-05-08 | 2021-11-10 | AiCuris GmbH & Co. KG | Letermovir for use in the prevention and the treatment of coronavirus infections |
US20240016901A1 (en) * | 2020-05-28 | 2024-01-18 | The Regents Of The University Of Michigan | Compositions and methods for preventing and treating sars-cov-2 infection |
WO2023083943A1 (en) | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals |
WO2023083951A1 (en) | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections |
WO2023083950A1 (en) | 2021-11-10 | 2023-05-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1455674B (zh) * | 2000-07-11 | 2019-03-29 | 艾库里斯有限及两合公司 | 绵羊副痘病毒菌株用于制备抗病毒药物和抗癌药物的用途 |
NZ523535A (en) * | 2000-07-11 | 2004-12-24 | Bayer Ag | Use of strains of the Parapoxvirus ovis against organ fibroses |
JP4897677B2 (ja) * | 2004-07-13 | 2012-03-14 | アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | Hiv/aidsの処置用の他の抗ウイルス剤と組み合わせたパラポックスウイルス |
EP1962841A1 (en) * | 2005-12-15 | 2008-09-03 | Bayer HealthCare AG | Diaryl urea for treating virus infections |
JP5699093B2 (ja) * | 2012-01-05 | 2015-04-08 | アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトAiCuris GmbH & Co. KG | パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物 |
WO2017015451A1 (en) * | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
-
2018
- 2018-09-06 TW TW107131294A patent/TW201919675A/zh unknown
- 2018-09-07 CA CA3075206A patent/CA3075206A1/en active Pending
- 2018-09-07 WO PCT/EP2018/074202 patent/WO2019048640A1/en unknown
- 2018-09-07 MX MX2020002605A patent/MX2020002605A/es unknown
- 2018-09-07 JP JP2020513816A patent/JP2020533314A/ja active Pending
- 2018-09-07 MA MA050071A patent/MA50071A/fr unknown
- 2018-09-07 SG SG11202001931WA patent/SG11202001931WA/en unknown
- 2018-09-07 AU AU2018327688A patent/AU2018327688B2/en active Active
- 2018-09-07 KR KR1020207009442A patent/KR20200051685A/ko not_active Application Discontinuation
- 2018-09-07 US US16/645,020 patent/US20200261520A1/en not_active Abandoned
- 2018-09-07 CN CN201880058406.1A patent/CN111093697A/zh active Pending
- 2018-09-07 BR BR112020004539-0A patent/BR112020004539A2/pt active Search and Examination
- 2018-09-07 CU CU2020000016A patent/CU20200016A7/es unknown
- 2018-09-07 GE GEAP201815308A patent/GEP20237518B/en unknown
- 2018-09-07 UY UY0001037869A patent/UY37869A/es not_active Application Discontinuation
- 2018-09-07 EP EP18762338.4A patent/EP3678697A1/en not_active Withdrawn
-
2020
- 2020-03-05 IL IL273093A patent/IL273093A/en unknown
- 2020-03-05 PH PH12020500445A patent/PH12020500445A1/en unknown
- 2020-03-05 CL CL2020000556A patent/CL2020000556A1/es unknown
- 2020-03-06 EC ECSENADI202016672A patent/ECSP20016672A/es unknown
-
2022
- 2022-08-02 JP JP2022123132A patent/JP2022167901A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202001931WA (en) | 2020-04-29 |
WO2019048640A1 (en) | 2019-03-14 |
MX2020002605A (es) | 2020-07-20 |
EP3678697A1 (en) | 2020-07-15 |
BR112020004539A2 (pt) | 2020-09-08 |
AU2018327688B2 (en) | 2022-12-01 |
CN111093697A (zh) | 2020-05-01 |
KR20200051685A (ko) | 2020-05-13 |
AU2018327688A1 (en) | 2020-03-19 |
ECSP20016672A (es) | 2020-06-30 |
CL2020000556A1 (es) | 2020-09-04 |
IL273093A (en) | 2020-04-30 |
MA50071A (fr) | 2020-07-15 |
CA3075206A1 (en) | 2019-03-14 |
JP2022167901A (ja) | 2022-11-04 |
GEP20237518B (en) | 2023-07-10 |
JP2020533314A (ja) | 2020-11-19 |
US20200261520A1 (en) | 2020-08-20 |
TW201919675A (zh) | 2019-06-01 |
PH12020500445A1 (en) | 2020-11-09 |
CU20200016A7 (es) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20016672A (es) | Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional | |
CY1123570T1 (el) | Τροποποιητες πυρηνικης πρωτεϊνης ηπατιτιδας β | |
CL2018002549A1 (es) | Eliminación del virus de la hepatitis b con agentes antivirales | |
CL2018002528A1 (es) | Agentes anti virales de la hepatitis b. | |
PH12017550022A1 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
CL2017002230A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb. | |
PH12016501762A1 (en) | Hepatitis b core protein allosteric modulators | |
GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
CR20170174A (es) | Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b | |
PH12018550207A1 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
CL2015001971A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas. | |
UY37962A (es) | Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
BR112017000320A2 (pt) | métodos para o tratamento de infecções virais de hepatite b e hepatite d | |
MX2017009812A (es) | Composiciones y metodos para inhibir infeccion viral. | |
PH12019550039A1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
WO2015058772A3 (en) | Novel hcv culture systems and direct-acting antiviral sensitivity | |
BR112015026243A2 (pt) | método de inibição viral | |
EA201590297A1 (ru) | Гетероциклические карбоксамиды для лечения вирусных заболеваний | |
WO2014210082A3 (en) | Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association | |
EA202090597A1 (ru) | Комбинированная терапия пациентов, инфицированных вирусом гепатита в (hbv), с использованием parapoxvirus ovis (ppvo) и по меньшей мере одного дополнительного противовирусного средства | |
AR112796A1 (es) | Terapias de combinación de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un fármaco antivírico adicional | |
MX2018000213A (es) | Metodos para tratar el vhc. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20231110 |